Acadia Pharmaceuticals (ACAD) EBT Growth (3y) (2013 - 2026)

Acadia Pharmaceuticals (ACAD) EBT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Acadia Pharmaceuticals 4.23 Bn 3.38 Bn 243.27 Mn 27.83%

Historic Data

Download Data
DateValue
Mar 31, 2026 27.83%
Dec 31, 2025 38.28%
Sep 30, 2025 54.52%
Jun 30, 2025 47.32%
Mar 31, 2025 30.98%
Dec 31, 2024 79.20%
Sep 30, 2024 66.59%
Jun 30, 2024 41.89%
Mar 31, 2024 32.31%
Dec 31, 2023 37.47%
Sep 30, 2023 15.01%
Jun 30, 2023 29.11%
Mar 31, 2023 20.10%
Dec 31, 2022 8.11%
Sep 30, 2022 14.50%
Jun 30, 2022 14.96%
Mar 31, 2022 -9.85%
Dec 31, 2021 13.14%
Sep 30, 2021 37.90%
Jun 30, 2021 11.71%